{"title":"Changing the Way We Approach Rehabilitation in Bone Marrow Transplantation","authors":"S. Abo, C. Granger","doi":"10.4172/2329-6917.1000236","DOIUrl":null,"url":null,"abstract":"Allogeneic bone marrow transplantation (alloBMT) is a highly intensive form of treatment for people with haematological cancer. Given its intensity and potential short and long term complications, there are significant risks of physical and psychological morbidity following treatment [1]. Several studies have identified that the side effects of an alloBMT can be long term and include physical impairments such as muscle weakness and reduced endurance; persistent symptoms such as fatigue; and poor health-related quality of life (HRQoL) [2,3]. Whilst the side effects observed in allogeneic and autologous BMT are similar, those experienced following an alloBMT are more numerous and severe due to prolonged hospital length of stay and greater risk of debilitating long-term complications such as graftversus-host-disease [1,4]. The survival rate for patients treated with alloBMT is increasing [5] and therefore as this chronic disease population increases in size, there is awareness of the need to focus on prevention of long-term morbidity and addressing patient survivorship needs.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"05 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of leukemia (Los Angeles, Calif.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2329-6917.1000236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Allogeneic bone marrow transplantation (alloBMT) is a highly intensive form of treatment for people with haematological cancer. Given its intensity and potential short and long term complications, there are significant risks of physical and psychological morbidity following treatment [1]. Several studies have identified that the side effects of an alloBMT can be long term and include physical impairments such as muscle weakness and reduced endurance; persistent symptoms such as fatigue; and poor health-related quality of life (HRQoL) [2,3]. Whilst the side effects observed in allogeneic and autologous BMT are similar, those experienced following an alloBMT are more numerous and severe due to prolonged hospital length of stay and greater risk of debilitating long-term complications such as graftversus-host-disease [1,4]. The survival rate for patients treated with alloBMT is increasing [5] and therefore as this chronic disease population increases in size, there is awareness of the need to focus on prevention of long-term morbidity and addressing patient survivorship needs.
同种异体骨髓移植(Allogeneic bone marrow transplantation, alloBMT)是血液学癌症患者的一种高度强化的治疗形式。鉴于其强度和潜在的短期和长期并发症,治疗bbb后存在显著的生理和心理发病率风险。一些研究已经确定同种异体bmt的副作用可能是长期的,包括身体损伤,如肌肉无力和耐力降低;持续性症状,如疲劳;健康相关生活质量(HRQoL)较差[2,3]。虽然同种异体和自体骨髓移植中观察到的副作用相似,但同种异体骨髓移植后的副作用更多、更严重,因为住院时间更长,出现长期并发症(如移植物抗宿主病)的风险更大[1,4]。接受同种异体bmt治疗的患者的生存率正在增加,因此,随着这种慢性疾病人群规模的增加,人们意识到需要关注预防长期发病率和解决患者生存需求。